FDA grants orphan drug status to Araim’s ARA 290 to treat sarcoidosis
The designation provides Araim with a seven year marketing exclusivity period against competition, and several incentives such as federal grants, tax credits and a waiver of PDUFA filing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.